TICKERNERD
Menu
GLMDGLMDHealthcare · Biotechnology

GLMD Stock Forecast: Galmed Pharmaceuticals Ltd. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.59
−5.80% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$5.1M
Ticker Nerd rank
19 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
+11.0%
1M
+2.6%
YTD
−22.1%
1Y
−62.3%
From 52W high
−64.1%
From 52W low
+24.7%
$0.47
$1.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GLMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Galmed Pharmaceuticals Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
73
Quality
39
Momentum
26
Issuance
26
Growth
25
Revisions
25
Volatility
21
Value
5

Size (95): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Galmed Pharmaceuticals Ltd. — and when they’d sell — is the membership.

Wall Street

GLMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.40$0.60$0.80$1.00$1.20$1.40$1.60Oct 25Jan 26Apr 26Jul 26GLMD

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Apr 2025Maxim GroupDowngradeHold—
24 July 2023Maxim GroupUpgradeBuy—
8 Aug 2022Canaccord GenuityDowngradeHold—
8 Aug 2022Maxim GroupDowngradeHold—
18 May 2022Raymond JamesDowngradeMarket Perform—
3 May 2022HC Wainwright & Co.DowngradeNeutral—
3 May 2022Raymond JamesMaintainsOutperform—
17 May 2021Canaccord GenuityMaintainsBuy—
19 Mar 2021HC Wainwright & Co.MaintainsBuy—
8 Jan 2021Raymond JamesMaintainsOutperform—
25 Nov 2020Canaccord GenuityMaintainsBuy—
22 May 2020B. Riley FBRDowngradeNeutral—
22 May 2020B. Riley SecuritiesDowngradeNeutral—
15 May 2020Raymond JamesMaintainsOutperform—
13 Mar 2020B. Riley FBRMaintainsBuy—
13 Mar 2020B. Riley SecuritiesMaintainsBuy—
13 Mar 2020StifelMaintainsBuy—
4 Feb 2020Craig-HallumInitiatesBuy—
30 Jan 2020Cantor FitzgeraldAssumesOverweight$59 → $14
22 July 2019Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

GLMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Galmed Pharmaceuticals Ltd. (GLMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
1.9×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−72.1%

Higher than 17% of US stocks

Return on assets
−33.5%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GLMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLMDGalmed Pharmaceuticals Ltd.$5.1M
19
APVOAptevo Therapeutics, Inc.$5.1M
10
HCWBHCW Biologics Inc.$5.1M
54
CLGNCollPlant Biotechnologies Ltd.$5.2M
33
JUNSJupiter Neurosciences, Inc.$5.1M
13
BRTXBioRestorative Therapies, Inc.$5.2M
8
GOVXGeoVax Labs, Inc.$5.0M
33
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GLMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest GLMD news & analysis

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

PRNewsWire · 28 July 2026positive

Galmed Pharmaceuticals announced the development of an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, which showed higher systemic bioavailability and increased central nervous system exposure compared to conventional oral administration in testing.

Why it matters — This development expands Galmed's pipeline beyond liver indications into neurodegenerative disease, potentially opening a new and large addressable market for the company's lead compound.

FAQ

Frequently asked questions about GLMD stock

Is GLMD stock a buy right now?

Of the 1 analysts covering Galmed Pharmaceuticals Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galmed Pharmaceuticals Ltd. 19 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLMD?

As at 1 Aug 2026, Galmed Pharmaceuticals Ltd. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the GLMD stock forecast for 2030?

No analyst covering Galmed Pharmaceuticals Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLMD are extrapolating price history, which says nothing about the business.

How has GLMD stock performed over the past year?

Galmed Pharmaceuticals Ltd. returned -62.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Galmed Pharmaceuticals Ltd. do?

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic solutions in the healthcare industry, particularly focusing on liver diseases.

What is the latest news on GLMD?

The most recent item we track (PRNewsWire, 28 July 2026): "Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market". Galmed Pharmaceuticals announced the development of an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, which showed higher systemic bioavailability and increased central nervous system exposure compared to conventional oral administration in testing.

Company

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic solutions in the healthcare industry, particularly focusing on liver diseases. Its primary aim is to address the unmet medical needs in the field of liver and metabolic diseases through innovative therapies. Galmed is notably recognized for its pioneering work on Aramchol, an investigational orally available drug, targeting Nonalcoholic Steatohepatitis (NASH) and other liver disorders. This therapeutic candidate plays a vital role in modulating lipid metabolism in the liver, which is a critical factor in the progression of NASH. Headquartered in Israel, Galmed Pharmaceuticals is at the forefront of research and development within its specialized niche, contributing significantly to the global biopharmaceutical landscape. The company's focus on niche markets like NASH underscores its strategic importance in potentially driving advancements in therapeutic options where current treatment paths are limited or non-existent, thus underscoring its potential impact on healthcare outcomes.

CEO Mr. Allen Baharaff · 3 employees · Israel · https://galmedpharma.com